Infantile Fibrosarcoma clinical trials at UC Cancer
1 research study open to eligible people
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
open to eligible people ages up to 30 years
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.
Our lead scientists for Infantile Fibrosarcoma research studies include Kieuhoa T. Vo.